Search research articles
Contact Us
Filters
Showing results (81-90 of 185) with videos related to
Page
of 19
Sort By:
Journal for Immunotherapy of Cancer
|
August 18, 2016
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Lucie Heinzerling, Patrick A Ott, F Stephen Hodi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 25, 2021
Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibition
Jianda Yuan, Anuradha Khilnani, Joshua Brody, et al.
Frontiers in Oncology
|
December 13, 2021
Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis
Melissa L Bastacky, Hong Wang, Dylan Fortman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 1, 2012
The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial
Jason J Luke, David R D'Adamo, Mark A Dickson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 17, 2014
Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA
Geoffrey R Oxnard, Cloud P Paweletz, Yanan Kuang, et al.
Science Immunology
|
February 23, 2020
Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes
Tianshi Lu, Shidan Wang, Lin Xu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 25, 2023
Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies
Jason J Luke, Sarina A Piha-Paul, Theresa Medina, et al.
Journal for Immunotherapy of Cancer
|
February 11, 2026
Phase 1 open-label study of ASP9801, an oncolytic virus, in patients with advanced or metastatic solid tumors
John L Villano, Jason J Luke, Ricklie Julian, et al.
Journal of Translational Medicine
|
November 27, 2019
BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma
Brian W Labadie, Ping Liu, Riyue Bao, et al.
Journal for Immunotherapy of Cancer
|
May 19, 2025
Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial
Jason J Luke, Katherine Bever, F Stephen Hodi, et al.
Page
of 19
Search research articles
Search
Showing results (81-90 of 185) with videos related to
Sort By:
Page
of 19
Journal for Immunotherapy of Cancer
|
August 18, 2016
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Lucie Heinzerling, Patrick A Ott, F Stephen Hodi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 25, 2021
Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibition
Jianda Yuan, Anuradha Khilnani, Joshua Brody, et al.
Frontiers in Oncology
|
December 13, 2021
Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis
Melissa L Bastacky, Hong Wang, Dylan Fortman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 1, 2012
The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial
Jason J Luke, David R D'Adamo, Mark A Dickson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 17, 2014
Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA
Geoffrey R Oxnard, Cloud P Paweletz, Yanan Kuang, et al.
Science Immunology
|
February 23, 2020
Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes
Tianshi Lu, Shidan Wang, Lin Xu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 25, 2023
Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies
Jason J Luke, Sarina A Piha-Paul, Theresa Medina, et al.
Journal for Immunotherapy of Cancer
|
February 11, 2026
Phase 1 open-label study of ASP9801, an oncolytic virus, in patients with advanced or metastatic solid tumors
John L Villano, Jason J Luke, Ricklie Julian, et al.
Journal of Translational Medicine
|
November 27, 2019
BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma
Brian W Labadie, Ping Liu, Riyue Bao, et al.
Journal for Immunotherapy of Cancer
|
May 19, 2025
Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial
Jason J Luke, Katherine Bever, F Stephen Hodi, et al.
Page
of 19